Ovzon-3 has reached its orbital position (5 months after launch) We expect orders picking up in H2.
We initiate coverage of Solwers, a company that acts as a growth platform for the built environment ...
Redeye in this note provides our first impressions on Acconeer’s CEO change that was announced yeste...
Redeye comments on recent news from Apple about its intention to open up its ecosystem to third-part...
Redeye initiates coverage of WntResearch, a Swedish biotechnology company specialised in oncology.
Med ett nytt godkännande i Danmark för en THC/CBD medicinsk cannabisolja har Stenocare återtagit pos...
CMS’ NTAP recommendation is positive, and we can expect a final decision by August, followed by a go...
Aptahem är ett bioteknikbolag som utvecklar ett läkemedel som har potential att definiera om behandl...
Redeye embraces the collaboration with Hanger, a leading amputee care and prosthetics provider with ...
Gapwaves announced its first Asian tier-1 customer with a development order worth SEK5.
Flexion to distribute Candy Crush on alternative app stores Potential revenue contribution of up to ...
Redeye ger en kort kommentar kring expertmötet om Donanemab.
Scanfil downgraded its full-year guidance on 10 June due to overall demand weakness.
Enrad AB (“Bolaget” eller “Enrad”) har fått två nya ordrar med ett totalt värde på 3,6 MSEK avseende...
Redeye provides a brief comment on the new partnership with Mid Sweden University and Sandvik.
